CCT

SI-BONE, Inc. Just Filed Its Quarterly Report: Net Loss Per Share o...

Net Loss Per Share of Common Stock

The table below summarizes the computation of basic and diluted net loss per share:
< td style="width:0.1%">
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(in thousands, except share and per share data)
Net loss
$(10,022)$(14,158)$(32,353)$(50,081)
Weighted-average shares used to compute basic and diluted net loss per share
40,265,520 34,356,850 37,702,207 34,069,357 
Net loss per share, basic and diluted
$(0.25)$(0.41)$(0.86)$(1.47)
Because the Company has reported a net loss in all periods presented, outstanding stock options, restricted stock units, ESPP purchase rights and common stock warrants are anti-dilutive and therefore diluted net loss per common share is the same as basic net loss per common share for the periods presented. The following anti-dilutive common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Stock options
1,216,8411,921,0651,216,8411,921,065 
Restricted stock units
2,501,2072,182,0302,501,2072,182,030 
ESPP purchase rights
38,72759,68838,72759,688 
Common stock warrants
85,139118,12285,139118,122 
3,841,914 4,280,905 3,841,914 4,280,905 

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever SI-BONE, Inc. makes a similar move, sign up!

Auto Refresh

Feedback